Key Highlights
- Shares of Co-Diagnostics (CODX) surged 9.43% to reach $2.90 during Friday’s premarket session
- CoSara Diagnostics, the firm’s Indian joint venture, secured an expansion agreement covering Bangladesh, Pakistan, Nepal, and Sri Lanka
- The deal increases CoSara’s South Asian addressable market to approximately $13 billion
- Key offerings planned for these markets include the PCR Pro® point-of-care device and SARAGENE® diagnostic products, subject to local regulatory clearance
- A virtual distributor session is scheduled for Q2 2026, with an in-person gathering planned for later in the summer
Shares of Co-Diagnostics (CODX) jumped 9.43% to $2.90 during Friday’s premarket session following news of a significant geographic expansion by the company’s Indian partnership.
CoSara Diagnostics Pvt. Ltd., a collaborative venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has finalized an arrangement to broaden its distribution footprint throughout South Asia. The agreement adds four nations to CoSara’s territory: Bangladesh, Pakistan, Nepal, and Sri Lanka.
This territorial addition expands CoSara’s projected addressable market within the region to roughly $13 billion, according to internal company assessments and external market intelligence.
The strategic expansion aims to facilitate the launch of two primary products: the CoSara PCR Pro® point-of-care testing system and the SARAGENE® diagnostic suite. Introduction in each territory remains contingent upon obtaining necessary regulatory permissions.
CoSara is actively developing distribution infrastructure throughout these four nations. Activities include navigating regulatory requirements, pinpointing priority customer groups, and partnering with regional distributors.
Executive Perspectives on Regional Growth
Mohal Sarabhai, CEO of CoSara, highlighted South Asia’s significant and expanding demand for convenient, non-invasive molecular diagnostics. He emphasized tuberculosis, HPV, and respiratory infection testing as critical application areas.
Dwight Egan, CEO of Co-Diagnostics, characterized the agreement as aligned with the company’s infrastructure-focused expansion approach. The strategy prioritizes establishing local production capabilities and distribution networks ahead of commercial launches—a framework being deployed across the United States, South Asia, and the MENA region.
Egan indicated the objective is to enable Co-Dx’s PCR point-of-care technology to scale effectively on a global basis.
To support distributor recruitment, CoSara will conduct a virtual informational session during Q2 2026, followed by an in-person distributor conference and training program later that summer.
Current Stock Performance
CODX had been trading close to its 52-week floor of $2.04 prior to Friday’s gains. The 9.43% premarket advance lifted shares to $2.90.
It bears mentioning that the PCR Pro® system and associated platform technologies remain under FDA evaluation and are not currently commercially available.
In March, Co-Diagnostics also secured a Japanese patent covering its PCR platform innovations. Previously, the company successfully regained NASDAQ listing compliance following a period of eligibility concerns.
The $13 billion total addressable market projection derives from company analyses and third-party research. Realized revenue opportunities will ultimately hinge on regulatory approvals and distributor network development across all four newly entered markets.
